FBIO
Fortress Biotech, Inc.
$2.77
+0.36%
$92.0M
No data for this timeframe.
Vol
Market Cap$92.0M
Cap SizeMicro Cap
Inst. Holders23 funds
Inst. Value$7.4M
Inst. Activity2 buys / 0 sells
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Recent Activity
May 19, 2026
other
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation
May 18, 2026
SEC
Fortress Biotech announced CEO participation in a fireside chat at A.G.P.'s Virtual Healthcare Conference. The filing is
PRESS-RELEASE — Impact 2/10
May 4, 2026
SEC
Fortress Biotech announced CEO participation in a fireside chat at the H.C. Wainwright Royalty Conference. No financial
PRESS-RELEASE — Impact 2/10
Apr 1, 2026
Insider
Jin David was granted 2,967 shares
Chief Financial Officer @ $2.18 ($6.5K)
Mar 18, 2026
Insider
ROSENWALD LINDSAY A MD was granted 475,424 shares
PRESIDENT, CEO & CHAIRMAN
Mar 18, 2026
Insider
WEISS MICHAEL S was granted 475,424 shares
Executive Vice Chairman
Inst.
STATE STREET CORP — ADD
101,601 shares ($283.5K)
Inst.
MORGAN STANLEY — ADD
3,884 shares ($10.8K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$11.00 (Feb 2026)
Current $2.77
Low $5.00
Median $11.00
High $17.00
2 analysts
$5.00
$17.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▼ -5.3% | $-0.20 — $-0.20 | -144% YoY | 1 |
| Next Q | $-0.15 ▲ +6.3% | $-0.15 — $-0.15 | -236% YoY | 1 |
| Current FY | $2.40 ▲ +442.9% | $2.40 — $2.40 | 3529% YoY | 1 |
| Next FY | $0.51 | $-0.50 — $1.51 | -79% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
2/10
Fortress Biotech announced CEO participation in a fireside chat at A.G.P.'s Virtual Healthcare Conference. The filing is
May 18, 2026
NEUTRAL
PRESS-RELEASE
2/10
Fortress Biotech announced CEO participation in a fireside chat at the H.C. Wainwright Royalty Conference. No financial
May 4, 2026
BULLISH
Press
8/10
Fortress Biotech announced the closing of the $205 million sale of a Rare Pediatric Disease Priority Review Voucher (PRV
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2.7M | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $793.2K | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $588.0K | — |
| BlackRock, Inc. | $549.9K | ADD |
| TWO SIGMA INVESTMENTS, LP | $549.1K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Jin David | A | $6.5K |
| Mar 18, 2026 | ROSENWALD LINDSAY | A | $0.00 |
| Mar 18, 2026 | WEISS MICHAEL | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
23 institutional holders with $7.4M total value (2,644,226 shares) as of 2026-Q1. Top holders: VANGUARD, SUSQUEHANNA, SUSQUEHANNA. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 966,030 | $2.7M | 36.5% | — |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 284,300 | $793.2K | 10.8% | — |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 210,745 | $588.0K | 8.0% | — |
| 4 | BlackRock, Inc. | 197,085 | $549.9K | 7.5% | ADD +43.7% |
| 5 | TWO SIGMA INVESTMENTS, LP | 196,825 | $549.1K | 7.4% | ADD +63.7% |
| 6 | CITADEL ADVISORS LLC | 180,289 | $503.0K | 6.8% | DOUBLED +282.6% |
| 7 | VANGUARD FIDUCIARY TRUST CO | 142,535 | $397.7K | 5.4% | — |
| 8 | HB Wealth Management, LLC | 120,175 | $335.3K | 4.5% | ADD +93.1% |
| 9 | STATE STREET CORP | 101,601 | $283.5K | 3.8% | ADD +31.5% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 99,590 | $277.9K | 3.8% | ADD +98.8% |
| 11 | PANAGORA ASSET MANAGEMENT INC | 56,668 | $158.1K | 2.1% | ADD +56.9% |
| 12 | CITADEL ADVISORS LLC | 29,100 | $81.2K | 1.1% | DOUBLED +282.6% |
| 13 | PRUDENTIAL FINANCIAL INC | 13,033 | $36.4K | 0.5% | ADD +45.1% |
| 14 | Vanguard Global Advisers, LLC | 12,578 | $35.1K | 0.5% | — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 11,600 | $32.4K | 0.4% | — |
| 16 | WELLS FARGO & COMPANY/MN | 10,575 | $29.5K | 0.4% | NEAR_EXIT -99.8% |
| 17 | Rockefeller Capital Management L.P. | 4,812 | $13.4K | 0.2% | — |
| 18 | MORGAN STANLEY | 3,884 | $10.8K | 0.1% | ADD +80.0% |
| 19 | FEDERATED HERMES, INC. | 1,261 | $3.5K | 0.0% | — |
| 20 | ROYAL BANK OF CANADA | 687 | $2.0K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 77,266 | 101,601 | +31.5% | $283.5K | 2026-Q1 |
| MORGAN STANLEY | ADD | 2,158 | 3,884 | +80.0% | $10.8K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 84,981 | 139,151 | +63.7% | $509.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 40,800 | 81,100 | +98.8% | $296.8K | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 15,382 | 63,692 | +314.1% | $233.1K | 2025-Q4 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 30,751 | 51,017 | +65.9% | $214.8K | 2025-Q4 |
| PANAGORA ASSET MANAGEMENT INC | ADD | 36,112 | 56,668 | +56.9% | $207.4K | 2025-Q4 |
| NATIONAL BANK OF CANADA /FI/ | NEAR_EXIT | 25,500 | 2,400 | -90.6% | $8.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 7,122 | 459 | -93.6% | $1.7K | 2025-Q4 |
| BlackRock, Inc. | ADD | 132,086 | 189,794 | +43.7% | $701.3K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 45,832 | 84,981 | +85.4% | $314.0K | 2025-Q3 |
| STATE STREET CORP | ADD | 43,966 | 69,266 | +57.5% | $255.9K | 2025-Q3 |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 50,065 | 36,112 | -27.9% | $133.4K | 2025-Q3 |
| UBS Group AG | TRIM | 43,155 | 30,290 | -29.8% | $111.9K | 2025-Q3 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 10,600 | 25,500 | +140.6% | $94.2K | 2025-Q3 |
| ENVESTNET ASSET MANAGEMENT INC | NEAR_EXIT | 169,713 | 22,286 | -86.9% | $82.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 696 | 7,122 | +923.3% | $26.3K | 2025-Q3 |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 267,908 | 169,713 | -36.7% | $315.7K | 2025-Q2 |
| UBS Group AG | DOUBLED | 12,659 | 43,155 | +240.9% | $80.3K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 175,800 | 32,000 | -81.8% | $49.9K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,457 | 11,338 | +361.5% | $17.7K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 20,749 | 1,950 | -90.6% | $3.0K | 2025-Q1 |
| CITIGROUP INC | NEAR_EXIT | 3,089 | 193 | -93.8% | $301.00 | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 9,006 | 16 | -99.8% | $25.00 | 2025-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 183,946 | 239,594 | +30.3% | $485.2K | 2024-Q4 |
3 unique insiders with 3 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Jin David | Chief Financial Officer | AWARD | 2,967 | $2.18 | $6.5K |
| Mar 18, 2026 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | AWARD | 475,424 | — | — |
| Mar 18, 2026 | WEISS MICHAEL S | Executive Vice Chairman | AWARD | 475,424 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 2.0/10.
Historical analyst distribution (last covering-analyst action Feb 2026): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$11.00 mean target (Feb 2026)
$5.00 Low
$17.00 High
| Metric | Value |
|---|---|
| Current Price | $2.77 |
| Target Low | $5.00 |
| Target Mean | $11.00 |
| Target Median | $11.00 |
| Target High | $17.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.20 | $-0.20 | -144.4% | -5.3% | 0↑ 1↓ | $0.0B | 11.5% | 1 |
| Next Q 2026-09-30 |
$-0.15 | $-0.15 | $-0.15 | -236.4% | +6.3% | 1↑ 0↓ | $0.0B | 26.4% | 1 |
| Current FY 2026-12-31 |
$2.40 | $2.40 | $2.40 | 3528.6% | +442.9% | — | $0.1B | 26.3% | 1 |
| Next FY 2027-12-31 |
$0.51 | $-0.50 | $1.51 | -79.0% | +0.0% | — | $0.1B | 68.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.200 | |
| 7d ago | $-0.190 | -0.010 |
| 30d ago | $-0.190 | -0.010 |
| 60d ago | $0.000 | -0.200 |
| 90d ago | $0.000 | -0.200 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Two Pharma Plays (FBIO & BCTX)
▲ 1
💬 0
⚡ 0.5
May 19, 2026
other
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,”
May 18, 2026
earnings
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical compa
May 14, 2026
earnings
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
<p align="center"><em>ZYCUBO<sup>®</sup> approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed
May 13, 2026
earnings
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
<p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p>
May 13, 2026
earnings_calendar
FBIO Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
earnings
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET <pre>Company to host confe
May 4, 2026
earnings
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
<p align="justify">MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical compa
Apr 21, 2026
contract
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 <pre>Payer
Mar 31, 2026
earnings
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
<p align="center"><em>ZYCUBO<sup>® </sup>approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold i
Mar 30, 2026
contract
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
<p align="justify">MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, C
Mar 25, 2026
earnings
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
<p align="center"><em>Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024</em></p>
Mar 24, 2026
earnings_calendar
FBIO Q4 2025 Earnings After Market Close — 2026-03-24
Mar 18, 2026
earnings
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET <pre>Company to host con
Jan 14, 2026
fda_pdufa
PDUFA: FBIO — CUTX-101 in Menkes disease — 2026-01-14
FDA target action date 2026-01-14 for FBIO (Fortress Biotech, Inc.). Drug: CUTX-101. Indication: Menkes disease. FDA accepted resubmission of NDA for